Sydney, June 22, 2026, 04:09 (AEST)
- ALS is set to enter the S&P/ASX 50 ahead of Monday’s open, taking the spot from Pro Medicus.
- Shares finished Friday at A$22.60, dropping 3.25% on the day. Still, they edged up roughly 0.3% for the week.
- Dividend reinvestment flows and the company’s growth view for FY2027 are set to drive trading in the near term.
ALS Ltd is set to join the S&P/ASX 50 before the Australian market opens on Monday, after a sharp fall in the stock on Friday. More index-tracking funds will now pick up the laboratory-testing firm. S&P announced the change on June 5, dropping Pro Medicus, the medical-imaging software group, from the index. Cash trading hadn’t started when this was published. ASX’s normal session begins about 10 a.m. Sydney.
ALS’s promotion is on investors’ radar because index-tracking funds might have to rebalance. Traders have had over two weeks to get ready, so some of the buying may already have played out. Where ALS opens Monday could show more about market positioning and liquidity than about the company itself.
ALS shares closed Friday at A$22.60, off A$0.76, or 3.25%. Despite Friday’s drop, the stock held about 0.3% over last week’s finish. The S&P/ASX 200 slid 0.92% to 8,828.70 in the last session of the week.
ALS’s dividend reinvestment plan is adding to short-term demand, as the company gives shareholders the choice to take stock in place of cash. The 23.1 Australian cent final dividend is set for July 3. DRP shares will be priced off the five-day volume-weighted average from June 17 to June 23. Macquarie Securities will handle the on-market buying. The company can issue new shares if enough stock can’t be bought on-market.
So now both the index reshuffle and DRP buying are pushing on the stock at the same time. Each can drive up turnover and skew the share price for a day or two. But neither force alters earnings or cash flow.
ALS is leaning on growth from the latest full year. For the year to March, ALS reported revenue of A$3.32 billion, up 10.7%. Underlying net profit came in at A$381.2 million, rising 25.8%. Statutory profit was A$318.7 million, up 24.4%. “Underlying” profit takes out certain acquisition, restructuring and other items management says aren’t part of normal operations.
Chief Executive Malcolm Deane said the numbers show “the resilience of our diversified portfolio” and “disciplined operational execution.” The group works in minerals testing, environmental analysis, food, and pharmaceuticals, which helps soften the blow if business drops in one segment. ALS Global
Peer numbers hint at steady, but not even, demand across the sector. Swiss group SGS said organic sales rose 5% in Testing and Inspection and 4.2% in Natural Resources for the first quarter, with Minerals driving gains. The timeframes and business splits aren’t one-to-one, but the data back the idea that testing volumes are holding up in much of the industry.
Risks are in focus. ALS is aiming for mid-to-high single-digit organic revenue growth in fiscal 2027, with Minerals set at 13% to 15%. Life Sciences wants to lift its margin by 30 to 50 basis points, or 0.30 to 0.50 percentage points. But the company has warned about weaker Environmental trading in the Americas, unfavorable foreign exchange, and a possible A$5 million to A$10 million hit to earnings from Middle East supply issues. If minerals exploration drops, hitting the Minerals goal gets tougher.
ALS could see heavy trading at the start of the week with Monday’s index inclusion and the DRP pricing period ending Tuesday. But after the hits from the index and dividend flows fade, investors still need to stay positive on the company’s growth and margin targets for fiscal 2027 for any gains to stick.
